InvestmentUpdated on 25 June 2026
Raising Series A for a Breakthrough Immune Tolerance Platform
Co-Founder & CEO at Integrated Nanotherapeutics
About
Integrated Nanotherapeutics (INT), a pre‑clinical company in Vancouver (Canada), is developing a multi‑cargo LNP platform that co‑delivers mRNA and small‑molecule immune modulators to induce antigen‑specific immune tolerance.
Our LNP drug delivery platform enables precise delivery of mRNA, small molecules, or both within a single nanoparticle, with tunable cargo release profiles. Our lead Type 1 Diabetes program has shown both prevention and reversal in animal models and received positive FDA feedback in 2025. We are opening a $25M Series A in Q2 2026 to advance INT-101 to Phase 1b/2a. The same mRNA-LNP platform has been successfully adapted to other autoimmune diseases by swapping in disease-specific antigens, demonstrating a flexible, plug‑and‑play approach for T‑cell–driven autoimmune diseases.
Stage
- Series A | Scale business
Organisation
Similar opportunities
Partnership
Co-development of immune tolerizing therapies
- Research
- Joint development
Chris Tam
Co-Founder & CEO at Integrated Nanotherapeutics
Partnership
α-Synuclein-Degrading Catalytide for Parkinson’s Disease (in vivo validated)
- Joint development
Toshifumi Akizawa
CEO at O-Force Co., Ltd.
Investment
Series A Investment Opportunity in Next-Generation Nucleic Acid Medicines
Pamela Housh
VP, Strategic Partnerships at Eyam Health